Product Candidate

BDTH₂

BDTH₂ (N,N′-bis-(2-mercaptoethyl) isophthalamide, NBMI, emeramide) is a thiol–redox antioxidant and metal chelator under evaluation for its potential to support cellular redox balance and metal binding. Its chemical structure supports penetration of cell membranes and has been reported to allow passage across the blood–brain barrier, suggesting that its effects are not confined to a single compartment or organ system.

A key feature of BDTH₂ is its capacity to scavenge and reduce hydroxyl free radicals, which are highly reactive species capable of disturbing normal cellular redox status and contributing to oxidative stress. In addition to these redox-modulating properties, BDTH₂ has shown notable versatility as a chelator. In vitro studies indicate that it can selectively bind toxic metal ions, particularly arsenic, as well as non-essential metals such as lead, cadmium, and uranium.

By forming stable complexes with these metals, BDTH₂ has demonstrated the ability to sequester toxic ions in experimental systems, with the potential to facilitate their elimination and limit metal-induced cellular toxicity. The two sulfhydryl groups of the cysteamine moieties in BDTH₂’s structure play a central role in this process, providing flexibility and rotational freedom that allow accommodation of a range of soft acid metal ions.

Available non-clinical and early clinical data suggest a favorable tolerability profile. In reported human studies, BDTH2 has generally been well tolerated, without dose-limiting toxicities identified within the investigated ranges. Further clinical work is required to define long-term safety, optimal dosing, and eventual therapeutic indications.

Bjørklund and colleagues have summarized the properties of BDTH₂ in the broader context of arsenic intoxication and metal chelation (1), highlighting its potential relevance in conditions characterized by toxic metal exposure and oxidative stress. Within Björklund Pharma’s program, BDTH₂ is being evaluated as a candidate for mechanism-based interventions targeting redox imbalance and metal overload, with future clinical applications dependent on robust preclinical and controlled clinical evidence. BDTH₂ is expected to remain covered by patents into the mid-2030s, after which Björklund Pharma AS may reassess independent supply, subject to legal and regulatory clearance..

Reference

1. Bjørklund G, Oliinyk P, Lysiuk R, Rahaman MS, Antonyak H, Lozynska I, Lenchyk L, Peana M. Arsenic intoxication: general aspects and chelating agents. Arch Toxicol 2020; 94: 1879-1897.